Vrije Universiteit Brussel

Marleen Keyaerts

Nick Devoogdt

Tony Lahoutte

Jo Van Ginderachter

Geert Raes

Jessica Bridoux

Karine Breckpot

Katrijn Broos

Quentin Lecocq

Catarina Xavier

The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human Programmed Death Ligand-1 (huPDL1) and to applications of such polypeptides such as for use as a medicament or for use as diagnostic agent, for example as an immunotracer.

Human PD-L1-binding immunoglobulins

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V) or a functional fragment thereof, wherein said Vor a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.

Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response

Growing community of inventors

Tervuren, Belgium

Marleen Keyaerts